NCT01154673View on ClinicalTrials.gov

Effects of Intensive cART During Acute/Early HIV Infection

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Acute HIV Infection
Interventions
DRUG

raltegravir

Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART

DRUG

maraviroc

Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART

DRUG

emtricitabine 200mg /tenofovir 300mg

emtricitabine 200mg /tenofovir 300mg QD

DRUG

lopinavir 400 mg/ritonavir 100mg

lopinavir 400 mg/ritonavir 100mg BID

Trial Locations (2)

M5B 1W8

University of Toronto, Toronto

M5G 1K2

Maple Leaf Medical Clinic, Toronto

Sponsors

Collaborators (1)

Maple Leaf Research
All Listed Sponsors
collaborator

Unity Health Toronto

OTHER

collaborator

Maple Leaf Research

OTHER

lead

University of Toronto

OTHER